Hook & thesis
Compass Therapeutics (CMPX) is a classic busted biotech set-up: a binary clinical disappointment - the lead asset failed a key overall survival secondary endpoint - pushed the stock into the deep discount bin, but the company still controls a platform and additional assets with standalone scientific value. The market has punished CMPX aggressively; the shares are trading at $1.17 and sitting on an RSI of 18.94, well into capitulation territory. That creates a narrow, time-limited trading opportunity ahead of two upcoming scientific exposures and potential short-covering dynamics.
My trade thesis: this is a speculative mid-term long (45 trading days) that buys oversold technicals and event optionality while accepting binary clinical and legal risks. Entry at $1.17, stop at $0.90, target at $2.50. Risk is high; position sizing should be small. The window is shrinking because the next material public presentation for tovecimig is scheduled for 10/24/2026 at ESMO and short interest is already elevated—if sentiment improves, the move can be sudden; conversely, further negative headlines can quickly erase gains.
What Compass Therapeutics does and why the market should care
Compass Therapeutics is a clinical-stage antibody therapeutics firm focused on modular bispecific antibodies and other engineered formats. The company operates a discovery and development platform built around common light chain-focused antibody discovery and modular bispecific constructs. That technical base is attractive to the market when data reads positively because bispecifics and novel checkpoint strategies remain high-value in oncology.
Practically speaking, the market is trading CMPX as a data story. The headline driver was tovecimig, a DLL4 x VEGF-A bispecific developed in combination with paclitaxel for advanced biliary tract cancer. The company disclosed that tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 trial, which pushed sentiment sharply negative. But Compass also has CTX-8371, a PD-1 x PD-L1 bispecific, which showed a 33% overall response rate at the highest dose levels in Phase 1 data presented at ASCO on 05/21/2026 — demonstrating that the platform can produce single-agent activity in checkpoint-refractory tumors. Those two threads - a failed OS result for one asset and encouraging early responses for another - are why the stock is volatile and why upcoming presentations matter.
Concrete numbers that matter
- Current price: $1.17 (last trade)
- Previous close: $1.24
- 52-week range: $1.1301 - $6.88 (high on 02/03/2026; low on 09/23/2026)
- Market cap: roughly $209.8M
- Shares outstanding: 180,088,000; public float ~136,566,133
- Reported EPS (TTM): -$0.41; price-to-book ~1.34
- Enterprise value: ~$187.9M; EV/EBITDA negative
- Cash (reported): 2.2 (units as reported)
- Volume today: ~2.4M; 30-day average volume: ~3.9M
- Short interest: ~40.79M shares (settlement 08/31), with days-to-cover roughly 17.26 at that snapshot
- Technicals: 10/20/50-day SMAs are all above current price (SMA20 ~$2.06, SMA50 ~$2.12); RSI 18.94; MACD shows bearish momentum.
Valuation framing
The market values Compass at about $210M. That price reflects both the disappointment on the tovecimig readout and the usual discount applied to unproven clinical-stage biotechs. With negative earnings (-$0.41 EPS) and EV/EBITDA in negative territory, standard multiple-based valuation is not helpful. Instead, the logic is binary: the company is being priced for failure (low single-digit dollars per share), while any favorable re-interpretation, incremental positive secondary endpoints, or encouraging commentary around CTX-8371 could re-rate the stock quickly. By comparison to its own 52-week high of $6.88, the current valuation implies the market has written off nearly all program value. For a trade, that asymmetry (deep downside priced in vs. meaningful upside possible on sentiment swing) is the attraction — but it is speculative and event-dependent.
Catalysts (what could move the stock)
- 10/24/2026 - ESMO oral presentation for tovecimig (DLL4 x VEGF-A) from COMPANION-002. Tone, subgroup analyses, safety re-interpretation, or positive secondary endpoints commentary could change the narrative.
- Follow-up analyses or additional CTX-8371 data; earlier Phase 1 showed a 33% ORR in the highest dose cohorts (ASCO 05/21/2026). Any new depth/duration data or expansion signals could be positive.
- Short-covering on a technical bounce. Short interest remains elevated (~40.8M shares as of 08/31 settlement), so a strong intraday bid could force squeezes and drive rapid upside.
- Corporate communications or partnering rumors that reframe the value of the platform or individual assets.
Trade plan (actionable)
Direction: Long
Entry: Buy at $1.17
Stop-loss: $0.90
Target: $2.50
Horizon: mid term (45 trading days) - roughly through the ESMO presentation window and the immediate post-event reaction. I expect the trade to play out over the next 6-9 weeks because the ESMO presentation on 10/24/2026 is the primary calendar event that can materially change sentiment; the 45-trading-day horizon captures pre-event positioning and the likely reaction period. If the stock moves above $2.50 earlier on strong volume and fundamentals, consider trimming to lock gains.
Position sizing: given the binary clinical and legal risks, size this as a speculative allocation (single-digit percentage of a diversified portfolio at most). Use the stop without hesitation; with options illiquidity likely, the stop is best executed with limit/market orders as fits your risk tolerance.
Why this entry makes tactical sense
First, technical oversoldness. RSI at 18.94 and price below the 10/20/50-day SMAs suggest capitulation. Second, there is real event optionality: ESMO on 10/24/2026 is an unavoidable tape that will force more eyes on the data and could produce clarifying detail around the COMPANION-002 readout. Third, short interest is substantial (roughly 40.8M shares on 08/31 settlement), providing the potential for squeezes if sentiment flips or buying exceeds expectations. Those three elements create a tactical asymmetry for a time-bound speculative buy.
Risks and counterarguments
- Binary clinical risk: tovecimig already failed a key overall survival secondary endpoint in COMPANION-002; further negative interpretation or durable lack of clinical benefit will further pressure shares.
- Regulatory/legal overhang: a securities investigation was announced on 04/27/2026 related to disclosures after the COMPANION-002 results. Litigation risk or additional disclosures could be materially negative.
- Capital and dilution risk: the company has executed public offerings in the past (an upsized $120M offering was priced in August 2025). If additional capital is required, expect dilution that could cap upside.
- Thin liquidity and volatility: average daily volumes vary; although 30-day average is ~3.9M, intraday swings can be violent and slippage can be significant, especially under news-driven moves.
- Platform/company-level execution risk: early promise from CTX-8371 does not guarantee later-line success; additional trials could fail or produce mixed data, undercutting the investment case.
Counterargument(s): Skeptics will point out that the tovecimig failure is not just a headline — it may reflect a true lack of survival benefit in the biliary tract cancer population, and investors are right to be cautious. The company’s market cap of roughly $209.8M may already reflect residual value in the platform and other programs; capital needs and a weak balance sheet can force dilutive raises that undercut any rebound. More fundamentally, even if short-term sentiment improves, true sustainable re-rating requires program-level clinical validation and clear partnering or regulatory paths.
What would change my mind
- I would abandon the long stance if the price breaks and holds below $0.90 on heavy volume, which would indicate continued downside momentum beyond a simple oversold bounce.
- I would also step back if the company announces materially dilutive financing terms or adverse legal developments that increase litigation risk materially.
- Conversely, I would become more constructive and consider a larger position if the ESMO presentation (10/24/2026) provides credible subgroup or secondary endpoint context that changes the narrative on tovecimig, or if CTX-8371 follow-ups show durable responses in additional cohorts.
Conclusion
Compass Therapeutics is a high-risk, event-driven opportunity. The stock is deeply oversold and cheap on headline metrics relative to prior highs, and upcoming scientific presentations create a window where sentiment can swing sharply. For traders willing to accept the binary risks, a small, well-sized speculative long at $1.17 with a $0.90 stop and a $2.50 target over a mid-term 45-trading-day horizon is a reasonable asymmetric play. If you own it, keep stakes small and respect the stop; if you prefer less risk, wait for clearer proof points on the platform or evidence that management has stabilized the narrative.